Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment o

[
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment o
[og_img]
https://www.investing.com/news/press-releases/actuate-therapeutics-presents-topline-elraglusib-phase-2-data-at-asco-2025-annual-meeting-trial-meets-primary-endpoint-of-median-overall-survival-and-doubles-1year-survival-in-firstline-treatment-o-93CH-4074349


Investing.com